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Abstract
There is currently limited information on clinical severity phenotypes of symptoms
and functional disability in post‐coronavirus disease 2019 (COVID) Syndrome (PCS).
A purposive sample of 370 PCS patients from a dedicated community COVID‐19
rehabilitation service was assessed using the COVID‐19 Yorkshire Rehabilitation
Scale where each symptom or functional difficulty was scored on a 0–10 Likert scale
and also compared with before infection. Phenotypes based on symptom severity
were extracted to identify any noticeable patterns. The correlation between
symptom severity, functional disability, and overall health was explored. The mean
age was 47 years, with 237 (64%) females. The median duration of symptoms was
211 days (interquartile range 143–353). Symptoms and functional difficulties in-
creased substantially when compared to before infection. Three distinct severity
phenotypes of mild (n = 90), moderate (n = 186), and severe (n = 94) were identified
where the severity of individual symptoms was of similar severity within each
phenotype. Symptom scores were strongly positively correlated with functional
difficulty scores (0.7, 0.6–0.7) and moderately negatively correlated with overall
health (−0.4, −0.3, to −0.5). This is the first study reporting on severity phenotypes in
a largely nonhospitalized PCS cohort. Severity phenotypes might help stratify pa-
tients for targeted interventions and planning of care pathways.
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1 | BACKGROUND
Post‐Coronavirus disease 2019 (COVID‐19) Syndrome (PCS) refers
to persistent symptoms 12 weeks after contracting COVID‐19
illness.1 There are an estimated more than a million cases of PCS in
the UK alone and more than 20 million cases worldwide.2 More than
200 symptoms across 10 organ systems have been reported with the
most common symptoms being fatigue, pain, breathlessness, palpi-
tations, dizziness, brain fog (cognitive problems), anxiety, depression,
posttraumatic stress, skin rash, and allergic reactions3 It is a remitting
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and relapsing condition with a protracted course causing significant
distress and disability to the individual.4
The symptoms and impact of PCS have been recorded in a
variety of ways, including the COVID Symptom Study digital appli-
cation5 and recently developed World Health Organisation clinical
platform Case Report Form (CRF).6 The Covid‐19 Yorkshire
Rehabilitation Scale (C19‐YRS) was the literature's first published and
validated patient‐reported outcome measure (PROM).7 It was
developed by our research team during the first wave of the
pandemic 8,9 and has been recommended by NICE and NHS England
to be used as an outcome measure at first assessment, 6 weeks and
6 months.10,11 The scale has been used in several PCS studies
supporting the content validity of the scale to reliably capture
persistent symptoms.12–14 Initial psychometric analysis of the scale
showed high internal consistency (Cronbach's alpha = 0.89) and good
concordance between the overall perception of health and patients'
reports of symptoms, functioning, and disability.7 The items of the
scale span all aspects of 2001 WHO International Classification of
Functioning, Disability, and Health (ICF) framework.8
Clinical symptom clusters or phenotypes have been mentioned in
the literature and some studies have tried to identify these clusters.
The Real‐Time Assessment of Community Transmission (REACT)
study analyzed more than half a million community cases and iden-
tified two symptom clusters – a large cohort with fatigue symptoms
and a smaller cohort with respiratory symptoms.2 The Post‐
hospitalization COVID‐19 study (PHOSP‐COVID) involving 1077
patients did not reveal symptom‐based phenotypes but identified
four clusters of posthospitalization outcomes with varying severities
of mental and physical health impairment (mild/moderate/severe/
very severe) with participants typically reporting nine persistent
symptoms five months after discharge.15
With the growing number of cases of PCS, there is a need to
understand symptom clusters, symptom severity, and interference
with daily functioning. By stratifying patients based on severity, ap-
propriate interventions and treatment plans can be prescribed, and
the trajectory of the condition mapped. The aim of this study was to
explore the presence of symptoms severity phenotypes in a com-
munity PCS cohort, including a large proportion of nonhospitalized
participants, and understand the relationship between severity of
symptoms, functional disability, and overall health in PCS.
2 | METHODS
2.1 | Setting
This service evaluation study was conducted within a COVID Re-
habilitation service in the North of England. This is a multidisciplinary
rehabilitation service, which offers specialist assessment and treatment
for PCS, delivered virtually and/or in person, delivered by a specialist
multidisciplinary team. Patients are referred via General Practitioners
(GPs) when symptoms have persisted beyond 12 weeks and cannot be
explained through alternative medical assessment. Patients were not
required to have had a positive polymerase chain reaction (PCR) test or
antibody test as these were not widely available to the general po-
pulation of the UK at the start of the pandemic.16
2.2 | Participant identification
Consecutive patients referred to the COVID Rehabilitation service
between February 2 and May 3, 2021 were considered for this ser-
vice evaluation study regardless of whether they had been previously
hospitalized with COVID‐19. All patients had agreed for their data to
be used anonymously for research purposes or service evaluation.
The eligible patients were prompted to complete the latest self‐
report version of C19‐YRS by one of the research team members. In
total, responses were received from 370 patients.
2.3 | C19‐YRS
The information gathered on C19‐YRS includes demographic in-
formation, medical history, and 16 key symptoms of PCS (including
breathlessness, persistent cough, fatigue, pain or discomfort, cog-
nitive problems, anxiety, depression, symptoms of posttraumatic
stress disorder [PTSD], palpitations, dizziness, weakness, and sleep
problems) and their impact on five daily functions (including com-
munication, mobility, personal care, wider activities of daily living,
and social functioning).8 Each symptom or functional ability is rated
by the respondent on a scale from 0 to 10 (0 being no presence of
symptom and 10 being most severe and life disturbing). Overall
health status is also captured on a 0–10 numerical rating scale
(NRS) scale. Unique to the C19YRS and this study, respondents are
also asked to grade their pre‐illness symptoms, functional
abilities, and overall health to provide a general clinical baseline for
comparison.
2.4 | Statistical analysis
Overall severity of the 12 most reported symptoms was defined as
the mean symptom score, with a mean score of 6 or more considered
“severe,” 3 to 5.9 “moderate”, and less than 3 “mild.” Demographic
details and brief clinical history were summarized overall and by
symptom severity. Functional abilities were reported on the same
0–10 scale.
All pairwise Spearman's correlations across symptoms and
functional abilities were calculated and presented graphically as a
heat map. Symptoms were then categorized as severe (6 or more) or
not, and the frequency of each combination of multiple severe
symptoms was presented as an UpSet diagram.
Cluster analysis was used to identify any groupings or
co‐occurrence of symptoms that could indicate potential different
phenotypes amongst the participants. Two approaches were used:
k‐means partition cluster analysis and a hierarchical agglomerative
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cluster analysis using average‐linkage between clusters and the
Euclidian dissimilarity measure. Robustness of results was assessed
using 2, 3, and 4 clusters and with different starting values (k‐means
cluster analysis) and using different weights and dissimilarity
measures (hierarchical cluster analysis). All statistical analyses were
carried out using Stata version 16.1 and R version 4.0.5.
2.5 | Ethical approval
Data were collected in the service as part of routine clinical evalua-
tion and ethical approval was obtained for the secondary analysis of
anonymized data collected for the primary clinical purpose which has
been completed. A favorable ethical opinion was received from the
University of Leeds School of Medicine Research Ethics Committee
(Ref MREC 20‐041).
3 | RESULTS
The majority of participants had not needed any hospitalization
during the infection (n = 304). The demographic measures and the
medical histories for all 370 patients are presented in Table 1. Pa-
tients had been experiencing persistent symptoms for a median of
211 days (interquartile range [IQR] 143–353) at the time of com-
pleting the C19‐YRS questionnaire. 237 (64%) of the patients were
female. The mean age was 47 years (SD = 14), with a mean body-
weight of 82 kg (SD = 22) and a mean body mass index (BMI) of
29 kg/m2 (SD = 8).
Patients were predominantly of white ethnicity (84%) with
only 57 patients (16%) from black, Asian, other, or mixed ethnic
groups, which is slightly lower than the proportion in the general
population of the region served (https://observatory.leeds.gov.uk/
population/). Patients from black and particularly Asian ethnic
groups reported experiencing more severe symptoms than pa-
tients from white ethnic groups.
Half (49%) of patients were still employed or studying on the
same hours as before infection with COVID‐19, and 41 (11%) were
in the same role as homemakers, still on maternity leave, retired or
unemployed. However, 144 (40%) had reduced their work hours,
were still on sick leave, or had stopped work altogether because of
ill health.
Table 2 shows the three severity phenotypes identified based on
their mean symptom score (6 or more considered “severe,” 3–5.9
“moderate”, and less than 3 “mild” as recommended by the C19‐YRS
scale). There was a tendency for patients with the most severe
symptoms to be more likely female, older, with higher weight or BMI.
Those with the most severe symptoms were half as likely to remain
employed on the same hours as those with the least severe
symptoms.
Radar plot mapping of the average individual symptom score for
each of the three categories (Figure 1) showed there was a gradient
in all 12 mean symptom scores, with patients who had greater overall
symptoms having each separate symptom higher on average with no
single symptom driving this association. For patients with milder
overall severity scores, fatigue was, on average, the dominant
symptom but all mean symptom scores were lower than those
deemed to have moderate severity overall. For patients with greater
overall severity scores, fatigue was joined by high mean symptom
scores across all 12 symptoms recorded, with all mean scores higher
than for the moderate category. There was a similar gradient in
functional difficulties, depending on the severity of the symptoms
(Figure 2). Hospitalized PCS patients reported similar severity levels
of persistent symptoms and functional abilities as nonhospitalized
patients
Fatigue was the most common symptom experienced, with
353 (95%) reporting this to some extent, followed by 334 (90%)
reporting anxiety, 329 (89%) some pain or discomfort, 316 (85%)
some breathlessness, and 315 (85%) some cognitive difficulties.
Overall symptom scores were negatively correlated with perceived
overall health (−0.4, −0.3 to −0.5) and positively correlated with
overall functional difficulty scores (0.7, 0.6–0.7). Figure 3 shows a
heat plot of the pairwise Spearman's correlation coefficients be-
tween each of the core PCS symptoms and associated functional
difficulties in the cohort.
The UpSet diagram in Figure 4 indicates that fatigue and pain or
discomfort were the symptoms most frequently experienced as se-
vere. These were experienced across the majority of symptom
combinations, with few combinations of severe symptoms that were
not combined with pain or fatigue, or both. There were no clear
subsets of mutually exclusive symptom combinations that would in-
dicate distinct symptom‐type phenotypes.
Cluster analysis did not identify any consistent symptom
groupings or phenotypes. Dendrograms from average‐linkage hier-
archical cluster analysis with Euclidean dissimilarity measures found
no distinct separation of subtypes (Figure 5), as indicated by relatively
short vertical lines at the top of the dendrogram and evenly spaced
dissimilarities across the cohort. This was consistent across different
weightings and dissimilarity measures (data not shown). There was
substantial overlap between patient symptoms to the extent that
applying k‐means cluster analysis with different initial starting values
for potential cluster means lead to different categorizations of in-
dividuals. The lack of evidence for clustering was also robust to the
number of clusters investigated, with cluster means largely defined
by the degree of symptom severity across all symptoms, rather than
with clustering of distinct types or classes of symptoms.
4 | DISCUSSION
This is the first study in the current literature from a community
specialist COVID‐19 rehabilitation service reporting on symptom
severity phenotypes in a cohort of largely nonhospitalized individuals.
We found the severity of a range of individual symptoms was related
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to the underlying severity of the condition, regardless of hospitali-
zation status during the acute phase of illness. The symptom severity
can be clearly categorized into mild, moderate, and severe severity
phenotypes. The severity of individual symptoms within each cate-
gory was similar with a strong correlation between symptoms se-
verity and functional difficulty and moderate correlation between
symptom severity and overall health status. Using a range of meth-
ods, we did not find evidence for phenotypes based on the type of
symptoms.
The severity of individual symptoms within each category being
similar might indicate a common underlying pathophysiological
mechanism for symptoms in PCS. This also explains the fluctuant
nature of the condition where the individual experiences flare‐up
of all symptoms (bad days) and symptom‐free days (good days). We
did not find any one symptom determining this association or
driving other symptoms which are again supportive of underlying
common mechanisms in the condition. We have some pointers in
the literature towards these common mechanisms in PCS such as
vascular damage (hypercoagulability),17 immune dysregulation,18
and dysautonomia.19 The reason for such a heterogeneous
presentation of symptoms in individuals needs to be explored in
future studies.
TABLE 1 Demographic measures and medical history of study participants by hospitalization status
All* Not hospitalized Hospitalized
(n = 370) (n = 304) (n = 66)
Female (%) 237 (64%) 208 (68%) 29 (44%)
Mean age (years) (SD) 47 (14) 46 (13) 53 (14)
Mean weight (kg) (SD) 82 (22) 80 (21) 93 (22)
Mean BMI (kg/m2) (SD) 29 (8) 28 (8) 32 (7)
Ethnicity (%)
White 307 (84%) 256 (86%) 51 (78%)
Black 10 (3%) 6 (2%) 6 (3%)
Asian 40 (11%) 30 (10%) 10 (15%)
Mixed/Other 7 (2%) 7 (2%) 0 (0%)
Smoking status (%)
Never smoked 235 (65%) 199 (67%) 36 (55%)
Current smoker 24 (7%) 22 (7%) 2 (3%)
Ex‐smoker 105 (29%) 78 (26%) 27 (42%)
Employment status (%)
Still employed/student 176 (49%) 155 (52%) 21 (33%)
Still retired/homemaker/unemployed 41 (11%) 34 (11%) 7 (11%)
Reduced hours 48 (13%) 44 (15%) 4 (6%)
Sick leave 77 (21%) 48 (16%) 29 (45%)
Stopped work 19 (5%) 16 (5%) 3 (5%)
Date of infection (%)
UK Wave 1 (March 2020–August 2020) 145 (39%) 128 (42%) 17 (26%)
UK Wave 2a (September 2020–November 2020) 120 (32%) 99 (33%) 21 (32%)
UK Wave 2b (December 2020–May 2021) 88 (24%) 61 (20%) 27 (41%)
UK Wave 3 (June 2021 onwards) 17 (5%) 16 (5%) 1 (2%)
Positive COVID‐19 test (%) 228 (62%) 182 (60%) 46 (70%)
Admitted to hospital (%) 66 (18%) 0 (0%) 66 (100%)
Median duration of symptoms (days) (IQR) 211 (143–353) 223 (150–355) 159 (129–288)
Abbreviations: BMI, body mass index; COVID‐19, coronavirus disease 2019; IQR, interquartile range; SD, standard deviation.
*Where numbers do not total 370, this is due to missing data.
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There is a concern in PCS that many symptoms such as fatigue or
anxiety or mood disorders may already be present in much of the
general population before infection. We were however able to show
in this study that, for a large number of symptoms, these were not
pre‐existing before infection, albeit scored retrospectively. This
supports the de novo (new‐onset) nature of the symptoms attribu-
table to the condition of PCS. The data collected in this study also
suggests that the C19‐YRS scale can be used to capture pre‐illness
symptoms even though there is likely to be a certain degree of re-
call bias.
Given the growing number of people with PCS (already more
than one million in the UK alone), the findings of severity phenotypes
in this study could have widespread implications for the provision and
resourcing of services to support people living with the condition.
The stratification based on the severity of cases could help national
and local providers to plan services and interventions that might be
directed towards these categories. Mild cases can be investigated in
Tier 3 primary care services (such as general practitioners) and of-
fered resources such as Your Covid recovery website20 or WHO self‐
management booklet.21 Moderate cases can be referred to Tier 2
TABLE 2 Demographic measures and medical history of study participants by overall symptom severity
All* Mild Moderate Severe
(n = 370) (n = 90) (n = 186) (n = 94)
Female (%) 237 (64%) 48 (53%) 125 (67%) 64 (68%)
Mean age (years) (SD) 47 (14) 47 (14) 47 (14) 50 (12)
Mean weight (kg) (SD) 82 (22) 79 (19) 81 (20) 88 (27)
Mean BMI (kg/m2) (SD) 29 (8) 27 (5) 28 (6) 32 (12)
Ethnicity (%)
White 307 (84%) 79 (88%) 156 (87%) 72 (77%)
Black 10 (3%) 1 (1%) 6 (3%) 3 (3%)
Asian 40 (11%) 5 (6%) 16 (9%) 19 (20%)
Mixed/Other 7 (2%) 5 (6%) 2 (1%) 0 (0%)
Smoking status (%)
Never smoked 235 (65%) 58 (65%) 120 (66%) 57 (62%)
Current smoker 24 (7%) 3 (3%) 13 (7%) 8 (9%)
Ex‐smoker 105 (29%) 28 (31%) 50 (27%) 27 (29%)
Employment status (%)
Still employed/student 176 (49%) 57 (66%) 87 (47%) 32 (35%)
Still retired/homemaker/unemployed 41 (11%) 11 (13%) 17 (9%) 13 (14%)
Reduced hours 48 (13%) 8 (9%) 31 (17%) 9 (10%)
Sick leave 77 (21%) 10 (12%) 35 (19%) 32 (35%)
Stopped work 19 (5%) 0 (0%) 14 (8%) 5 (5%)
Date of infection (%)
UK Wave 1 (March 2020–August 2020) 145 (39%) 36 (40%) 71 (38%) 38 (40%)
UK Wave 2a (September 2020–November 2020) 120 (32%) 31 (34%) 65 (35%) 24 (26%)
UK Wave 2b (December 2020–May 2021) 88 (24%) 20 (22%) 42 (23%) 26 (30%)
UK Wave 3 (June 2021 onwards) 17 (5%) 3 (3%) 8 (4%) 6 (6%)
Positive COVID‐19 test (%) 228 (62%) 49 (54%) 122 (66%) 57 (61%)
Admitted to hospital (%) 66 (18%) 17 (19%) 25 (13%) 24 (26%)
Median duration of symptoms (days) (IQR) 211 (143–353) 211 (144–359) 196 (142–354) 223 (145–346)
Abbreviations: BMI, body mass index; COVID‐19, coronavirus disease 2019; IQR, interquartile range; SD, standard deviation.
*Where numbers do not total 370, this is due to missing data.
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community PCS services where specialist therapy input can be pro-
vided. Severe cases need Tier 1 specialist multidisciplinary (MDT)
investigations and interventions.16,22
One weakness of many previous studies has been the reliance on
cohorts entirely comprised of individuals previously hospitalized with
COVID‐19. Our inclusion of a large proportion of nonhospitalized
patients, and the consistency of their symptoms with those of hos-
pitalized patients, implies that our reported symptoms are unlikely to
be a result of the hospital or intensive care experience but are due to
the unique underlying pathophysiological mechanism of PCS. This is
in keeping with other studies which have shown a similar burden of
symptoms in nonhospitalized patients.23
It is important to remember that PCS is a fluctuating or epi-
sodic condition and that symptom severity can vary over time
within the same individual.24 Capturing this fluctuation of severity
and personal triggers (physical, cognitive, emotional) may help in-
dividuals stay within the limits of these triggers and pace their
activities accordingly, to avoid worsening of symptom severity and
its functional impact. We recommend complex multifaceted re-
habilitation interventions to manage symptom severity fluctuation
seen in PCS.16
There are some limitations to this study. First, a relatively small
sample size precludes determining distinct symptom‐based
phenotype patterns to be estimated with sufficient precision to be
identified. It is possible that rarer phenotypes exist that did not
present with sufficient numbers in our study sample. Instead, all
groupings of individual symptoms based on correlations between
them were dominated by the overall severity across all symptoms.
Second, it is worth noting that symptoms and their severity were self‐
reported by patients, so there could be a degree of subjectivity in
their recording, that they tend to grade severity similar across the
symptoms. It is possible that milder cases not presenting to PCS
centers for management might present with more distinct symptom
clusters that would indicate different underlying pathophysiological
mechanisms. Finally, there is an element of recall bias in reporting
pre‐illness scores, but this had no bearing on the findings of this
study.
5 | CONCLUSIONS
This is the first study in the current literature reporting on severity
phenotypes in a largely nonhospitalized PCS cohort. Severity phe-
notypes might help stratify patients for targeted interventions and
planning of care pathways. Further research is needed to understand
the common mechanisms and pathophysiological basis of PCS.
F IGURE 1 Radar plot of mean severity of
12 persistent long‐COVID symptoms, scored
from 0 to 10, by overall severity of the condition.
COVID, coronavirus disease
F IGURE 2 Radar plot of mean severity of
5 functional difficulties, scored from 0 to 10,
by overall severity of the condition
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F IGURE 3 Heat plot displaying the pairwise correlation between core symptoms and functional difficulties. The color gradient reflects the
strength of the correlation, with the darker colors indicating stronger correlation
F IGURE 4 UpSet diagram showing the frequency of different combinations of severe symptoms for Post‐COVID Syndrome
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Specific symptom‐based phenotype could not be identified in this
cohort but needs to be explored in larger population studies.
ACKNOWLEDGMENTS
NHS England clinical guidance suggests the use of the C19‐YRS at
first assessment, at six weeks, and at 6 months in PCS. National
Institute for Health and Care Excellence (NICE) recommends the use
of C19‐YRS for a comprehensive assessment of PCS patients. This
study is supported by the University of Leeds Medical Research
Council (MRC) Confidence in Concept (CiC) grant for development of
C19‐YRS. Manoj Sivan, Amy Parking, and Darren Greenwood are also
supported by the Long Covid research grant from National Institute
for Health Research (NIHR). Manoj Sivan is associated with the NIHR
Leeds Biomedical Research Centre (BRC).
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
Manoj Sivan conceptualized the study, led the development of the
C19‐Yorkshire Rehabilitation Scale, and led the writing of the
manuscript. Amy Parkin, Sophie Makower, and Manoj Sivan were
responsible for the data collection and organization and contributed
to the writing of the final drafts of the manuscript. Darren
Greenwood is the senior biostatistician in the team and performed all
the statistical analyses presented in the draft and contributed to the
writing of the manuscript.
DATA AVAILABILITY STATEMENT
The data sets used and analyzed during the current study are avail-
able from the corresponding author on reasonable request.
ORCID
Manoj Sivan http://orcid.org/0000-0002-0334-2968
Darren C. Greenwood http://orcid.org/0000-0001-7035-3096
REFERENCES
1. Excellence NIFC. Covid‐19 rapid guideline: managing the long‐term
effects of covid‐19. 2021.
2. Whitaker M, Elliott J, Chadeau‐Hyam M, et al. Persistent symptoms
following SARS‐CoV‐2 infection in a random community sample of
508,707 people. medRxiv. 2021.
3. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in
an international cohort: 7 months of symptoms and their impact.
EClinicalMedicine. 2021;38:101019.
4. Sivan M, Rayner C, Delaney B. Fresh evidence of the scale and scope
of long covid. BMJ. 2021;373:n853.
5. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of
long COVID. Nat Med. 2021;27(4):626‐631.
6. World Health Organization. Global COVID‐19 clinical platform case
report form (CRF) for post COVID condition (post COVID‐19
CRF). 2021.
7. O'Connor RJ, Preston N, Parkin A, et al. The COVID‐19 Yorkshire
Rehabilitation Scale (C19‐YRS): application and psychometric
analysis in a post‐COVID‐19 syndrome cohort. J Med Virol.
Published online October 21, 2021.
8. Sivan M, Halpin S, Gees J, et al. The self‐report version and digital
format of the COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS)
for Long Covid or Post‐COVID syndrome assessment and
F IGURE 5 Dendrogram showing the first 100 leaves from agglomerative average linkage cluster analysis. The numbers at the foot of each
branch indicate the size of each leaf
8 | SIVAN ET AL.
monitoring. Advances in Clinical Neurosciences and Rehabilitation.
2021;20(3):1‐5.
9. Sivan M, Halpin SJ, Gee J. Assessing long‐term rehabilitation needs
in COVID‐19 survivors using a telephone screening tool (C19‐YRS
tool). ACNR. 2020;2020(19):14‐17.
10. New England National guidance for post‐COVID syndrome assess-
ment clinics. 2021.
11. Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:
m4938.
12. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and
rehabilitation needs in survivors of COVID‐19 infection: A cross‐
sectional evaluation. J Med Virol. 2021;93(2):1013‐1022.
13. Kayaaslan B, Eser F, Kalem AK, et al. Post‐COVID syndrome:
A single‐center questionnaire study on 1007 participants recovered
from COVID‐19. J Med Virol. 2021;93:6566‐6574.
14. Hafeez MM, Azhar M, Chudhary HRZ, Rana MA, Malik A. Innovation
of audio‐visual triage system in combating the spread of COVID‐19
infection and its efficacy: a novel strategy. medRxiv. 2020.
15. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, SerenoM.
Physical, cognitive and mental health impacts of COVID‐19 following
hospitalisation: a multi‐centre prospective cohort study.medRxiv. 2021.
16. Parkin A, Davison J, Tarrant R, et al. A multidisciplinary NHS COVID‐19
service to manage post‐COVID‐19 syndrome in the community. J Prim
Care Community Health. 2021;12:21501327211010994.
17. Nalbandian A, Sehgal K, Gupta A, et al. Post‐acute COVID‐19 syn-
drome. Nat Med. 2021;27(4):601‐615.
18. Phetsouphanh C, Darley D, Wilson DB, Howe A, Mee C,
Munier CML. Immunological dysfunction persists for 8 months fol-
lowing initial mild‐moderate SARS‐CoV‐2 infection. medRxiv. 2021.
19. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in
‘long COVID’: rationale, physiology and management strategies. Clin
Med (Lond). 2021;21(1):e63‐e67.
20. New England. Your Covid Recovery. 2020.
21. WHO. Support for rehabilitation: self‐management after COVID‐19‐
related illness. Copenhagen: WHO Regional Office for Europe.
2021. https://apps.who.int/iris/handle/10665/344472
22. Sivan M, Halpin S, Hollingworth L, Snook N, Hickman K, Clifton IJ.
Development of an integrated rehabilitation pathway for individuals
recovering from COVID‐19 in the community. J Rehabil Med. 2020;
52(8):jrm00089.
23. Taquet M, Dercon Q, Harrison PJ. Six‐month sequelae of post‐
vaccination SARS‐CoV‐2 infection: a retrospective cohort study of
10,024 breakthrough infections. medRxiv. 2021.
24. Adhikari SP, Shrestha P, Dev R. Feasibility and effectiveness of
telephone‐based telephysiotherapy for treatment of pain in low‐
resource setting: a retrospective pre‐post design. Pain Res Manag.
2020;2020:2741278.
How to cite this article: Sivan M, Parkin A, Makower S,
Greenwood DC. Post‐COVID syndrome symptoms, functional
disability, and clinical severity phenotypes in hospitalized and
nonhospitalized individuals: A cross‐sectional evaluation from
a community COVID rehabilitation service J Med Virol. 2021;
1‐9. doi:10.1002/jmv.27456
SIVAN ET AL. | 9
